AR087155A1 - Formulacion granulada de azaperona de rapida disolucion - Google Patents
Formulacion granulada de azaperona de rapida disolucionInfo
- Publication number
- AR087155A1 AR087155A1 ARP120102160A ARP120102160A AR087155A1 AR 087155 A1 AR087155 A1 AR 087155A1 AR P120102160 A ARP120102160 A AR P120102160A AR P120102160 A ARP120102160 A AR P120102160A AR 087155 A1 AR087155 A1 AR 087155A1
- Authority
- AR
- Argentina
- Prior art keywords
- azaperone
- granulated formulation
- acid
- fast
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 title abstract 4
- 229950003616 azaperone Drugs 0.000 title abstract 4
- 238000004090 dissolution Methods 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- 239000005913 Maltodextrin Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229960001375 lactose Drugs 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 229940035034 maltodextrin Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000000273 veterinary drug Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación granulada de rápida disolución que contiene el fármaco veterinario azaperona y un método para preparar la formulación granulada.Reivindicación 1: Una formulación granulada de rápida disolución caracterizada porque comprende: azaperona; un ácido seleccionado de ácido tartárico o ácido cítrico; un rellenador seleccionado de lactosa, monohidrato de lactosa, o manitol; un aglutinante seleccionado de maltodextrina, HPMC, o povidona; y opcionalmente un agente colorante; de este modo la relación de azaperona : ácido es entre aproximadamente 1:2 hasta aproximadamente 1:4 (p/p). Reivindicación 24: Un método para administrar la formulación de conformidad con cualquiera de las reivindicaciones 1 a 23 a un animal, caracterizado porque la administración es vía un sistema de distribución de agua.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11171263A EP2537518A1 (en) | 2011-06-24 | 2011-06-24 | Fast dissolving azaperone granulate formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087155A1 true AR087155A1 (es) | 2014-02-26 |
Family
ID=44280773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102160A AR087155A1 (es) | 2011-06-24 | 2012-06-18 | Formulacion granulada de azaperona de rapida disolucion |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9339464B2 (es) |
| EP (2) | EP2537518A1 (es) |
| JP (1) | JP5984923B2 (es) |
| KR (1) | KR101497866B1 (es) |
| CN (1) | CN103619335B (es) |
| AR (1) | AR087155A1 (es) |
| AU (1) | AU2012272935B2 (es) |
| BR (1) | BR112013032608A2 (es) |
| CA (1) | CA2836497C (es) |
| CL (1) | CL2013003663A1 (es) |
| CO (1) | CO6862149A2 (es) |
| EA (1) | EA024030B1 (es) |
| MX (1) | MX2013014796A (es) |
| PH (1) | PH12014500021A1 (es) |
| TW (1) | TWI555538B (es) |
| WO (1) | WO2012177842A1 (es) |
| ZA (1) | ZA201309511B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102015122672A1 (de) | 2015-12-23 | 2017-06-29 | Brauns-Heitmann Gmbh & Co. Kg | Pulverförmige Eierfärbemittelzusammensetzung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69834255T2 (de) * | 1997-07-25 | 2006-09-28 | Alpex Pharma S.A. | Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten |
| JP2001015070A (ja) | 1999-06-29 | 2001-01-19 | Ushio Inc | 放電ランプ |
| GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
| US20040156894A1 (en) * | 2003-02-07 | 2004-08-12 | Grother Leon Paul | Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |
| KR20110070861A (ko) | 2008-09-18 | 2011-06-24 | 얀센 파마슈티카 엔.브이. | 항생제 사용을 감소시키기 위한 아자페론의 용도 |
| PL2346349T3 (pl) | 2008-09-18 | 2015-03-31 | Elanco Animal Health Ireland | Zastosowanie azaperonu do poprawy wskaźników wzrostu |
-
2011
- 2011-06-24 EP EP11171263A patent/EP2537518A1/en not_active Withdrawn
-
2012
- 2012-06-13 TW TW101121205A patent/TWI555538B/zh not_active IP Right Cessation
- 2012-06-18 AR ARP120102160A patent/AR087155A1/es unknown
- 2012-06-21 US US14/127,018 patent/US9339464B2/en not_active Expired - Fee Related
- 2012-06-21 MX MX2013014796A patent/MX2013014796A/es not_active Application Discontinuation
- 2012-06-21 JP JP2014517148A patent/JP5984923B2/ja not_active Expired - Fee Related
- 2012-06-21 WO PCT/US2012/043499 patent/WO2012177842A1/en not_active Ceased
- 2012-06-21 PH PH1/2014/500021A patent/PH12014500021A1/en unknown
- 2012-06-21 EA EA201391707A patent/EA024030B1/ru not_active IP Right Cessation
- 2012-06-21 AU AU2012272935A patent/AU2012272935B2/en not_active Ceased
- 2012-06-21 KR KR1020137033761A patent/KR101497866B1/ko not_active Expired - Fee Related
- 2012-06-21 CA CA2836497A patent/CA2836497C/en not_active Expired - Fee Related
- 2012-06-21 EP EP12730766.8A patent/EP2723341A1/en not_active Withdrawn
- 2012-06-21 CN CN201280031242.6A patent/CN103619335B/zh not_active Expired - Fee Related
- 2012-06-21 BR BR112013032608A patent/BR112013032608A2/pt not_active IP Right Cessation
-
2013
- 2013-12-11 CO CO13290179A patent/CO6862149A2/es active IP Right Grant
- 2013-12-17 ZA ZA2013/09511A patent/ZA201309511B/en unknown
- 2013-12-20 CL CL2013003663A patent/CL2013003663A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391707A1 (ru) | 2014-05-30 |
| CA2836497C (en) | 2016-02-16 |
| KR20140014290A (ko) | 2014-02-05 |
| TW201302245A (zh) | 2013-01-16 |
| BR112013032608A2 (pt) | 2017-01-24 |
| AU2012272935A1 (en) | 2013-11-28 |
| MX2013014796A (es) | 2014-01-24 |
| AU2012272935B2 (en) | 2015-07-16 |
| CO6862149A2 (es) | 2014-02-10 |
| JP5984923B2 (ja) | 2016-09-06 |
| KR101497866B1 (ko) | 2015-03-02 |
| EP2723341A1 (en) | 2014-04-30 |
| PH12014500021A1 (en) | 2014-02-17 |
| CN103619335A (zh) | 2014-03-05 |
| ZA201309511B (en) | 2015-09-30 |
| CL2013003663A1 (es) | 2014-09-05 |
| CA2836497A1 (en) | 2012-12-27 |
| US9339464B2 (en) | 2016-05-17 |
| EP2537518A1 (en) | 2012-12-26 |
| CN103619335B (zh) | 2015-09-30 |
| TWI555538B (zh) | 2016-11-01 |
| EA024030B1 (ru) | 2016-08-31 |
| WO2012177842A1 (en) | 2012-12-27 |
| US20140128407A1 (en) | 2014-05-08 |
| JP2014517071A (ja) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| CL2019001447A1 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos. | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| PH12021550537A1 (en) | Oral formulations of kappa opioid receptor agonists | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| MX2012005365A (es) | Formulaciones de tableta de liberacion inmediata. | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| AR105203A1 (es) | Formulación oral sólida que contiene irinotecán y método de preparación de la misma | |
| CO6351716A2 (es) | Formulación de liberación modificada y métodos de uso | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| MX369742B (es) | Formulación de liberación modificada. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| PE20181369A1 (es) | Suspensiones orales acuosas fisica y quimicamente estables de givinostat | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| GEP20247606B (en) | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| AR087155A1 (es) | Formulacion granulada de azaperona de rapida disolucion | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| AR097202A1 (es) | Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa | |
| NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| MX2020003697A (es) | Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |